The inhibition of c-MET using the non-specific pan-kinase inhibitor crizotinib [139] or the MET-specific HS-10,241 [140] abolishes Tyr907 phosphorylation, sensitizing to PARPi in in vitro and xenograft models of TNBC, NSCLC, and high-grade serous ovarian cancer (HGSOC), independent of BRCA status. The gene discussed is MET; the disease is ovarian serous adenocarcinoma.